Innocoll is a biotherapeutics pharmaceutical company focused on the development and commercialization of pharmaceutical technologies to meet some of today’s most important healthcare challenges.
We utilize our proprietary collagen-based technology platform to develop biodegradable and fully resorbable products. Our processes and technologies enable us to control the drug elution dynamics, texture, consistency, resorption time and other physical characteristics of the finished product. All of our native collagen products are manufactured at our certified, state-of-the-art, fully integrated plant in Saal, Germany.
Our current late-stage product pipeline is focused on addressing patient needs for postsurgical pain management.
Our lead product using this proprietary technology, Xaracoll® (bupivacaine HCl) Implant, was approved by the U.S. Food and Drug Administration in August 2020.